Výsledky vyhledávání - "Joseph Glajch"

Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple Sclerosis

Autor: Richard Sachleben, James Roach, Tanmoy Ganguly, Benjamin Greenberg, Jonathan C. Lansing, Daniel Kantor, Ian Fier, James H. Prescott, Hall Steven E, Christine Bell, Paul J. Miller, Kavita V. Nair, Kristina Storey, Ishan Capila, Joseph Glajch, James M. Anderson, Mani Iyer

Publikováno v: Journal of pharmacy practice, vol 31, iss 5

The multiple sclerosis (MS) treatment landscape in the United States has changed dramatically over the past decade. While many disease-modifying therapies (DMTs) have been approved by the US Food and Drug Administration (FDA) for the treatment of rel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca70b152ba0ebfb57b69915a776b609b
https://escholarship.org/uc/item/8k30d36z

Zobrazit plný text záznamu

Demonstration of equivalence of a generic glatiramer acetate (Glatopa™)

Autor: Jonathan C. Lansing, James Anderson, Christine Bell, James H. Prescott, John Bishop, Joseph Glajch, Ishan Capila, Richard Sachleben, Bruce A. Cohen, Mani Iyer, Daniel Kantor, Ganesh Kaundinya, Joel Pradines, Tanmoy Ganguly

Publikováno v: Journal of the Neurological Sciences. 359:24-34

Glatiramer acetate (GA) has been available under the brand name Copaxone® for nearly two decades. Recently, the US Food and Drug Administration (FDA) approved the first generic GA, Glatopa™, as fully substitutable for all indications for which Cop

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e9685fe7cfcc8113789c68001c56f186
https://doi.org/10.1016/j.jns.2015.10.007

Zobrazit plný text záznamu

Two decades of glatiramer acetate: From initial discovery to the current development of generics

Autor: Kavita V. Nair, Daniel Kantor, Joseph Glajch, Tanmoy Ganguly, Bianca Weinstock-Guttman

Publikováno v: Journal of the neurological sciences. 376

Multiple sclerosis (MS) is a chronic, incurable, inflammatory disease of the central nervous system (CNS). In the United States, several US Food and Drug Administration (FDA)-approved disease-modifying treatments (DMTs) are available, including glati

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::341b50bdf8463e0a5beadf918166d9d5
https://pubmed.ncbi.nlm.nih.gov/28431621

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání